Cargando…

Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials

BACKGROUND: Erenumab, a fully human monoclonal antibody that targets the calcitonin gene-related peptide receptor, has demonstrated efficacy and safety in the prevention of episodic and chronic migraine. There exists an unmet need to establish the safety of erenumab in older individuals, in view of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lampl, Christian, Kraus, Viktoria, Lehner, Katrina, Loop, Brett, Chehrenama, Mahan, Maczynska, Zofia, Ritter, Shannon, Klatt, Jan, Snellman, Josefin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386939/ https://www.ncbi.nlm.nih.gov/pubmed/35978286 http://dx.doi.org/10.1186/s10194-022-01470-4

Ejemplares similares

Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018)

One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study
por: Goadsby, Peter J., et al.
Publicado: (2020)

Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India
por: Chowdhury, Debashish, et al.
Publicado: (2022)

Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis
por: Kitamura, Shigekazu, et al.
Publicado: (2023)

Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020)

Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
por: Alsaadi, Taoufik, et al.
Publicado: (2022)

The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
por: Broessner, Gregor, et al.
Publicado: (2020)

Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data
por: Dodick, David W., et al.
Publicado: (2021)

Timing and durability of response to erenumab in patients with chronic migraine
por: Tepper, Stewart J., et al.
Publicado: (2021)

The role of erenumab in the treatment of migraine
por: Andreou, Anna P., et al.
Publicado: (2020)

The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN)
por: Filippi, Massimo, et al.
Publicado: (2023)

Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials
por: Tepper, Stewart J, et al.
Publicado: (2021)

Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study
por: Lanteri-Minet, Michel, et al.
Publicado: (2021)

A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults
por: Sakai, Fumihiko, et al.
Publicado: (2019)

Real-Life Analysis with Erenumab: First Target Therapy in the Episodic and Chronic Migraine’s Prophylaxis
por: Maraia, Zaira, et al.
Publicado: (2021)

Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice
por: Storch, P., et al.
Publicado: (2021)

Optimal Dose of Erenumab for Preventive Treatment of Episodic Migraine: A Systematic Review and Meta-Analysis
por: Yang, Yanbo, et al.
Publicado: (2022)

Assessment and characteristics of Erenumab therapy on migraine management
por: Saeed, Haitham, et al.
Publicado: (2022)

Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study
por: Gladstone, Jonathan, et al.
Publicado: (2021)

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
por: Ashina, Messoud, et al.
Publicado: (2019)

Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study
por: Cullum, Christopher Kjaer, et al.
Publicado: (2022)

Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
por: Ornello, Raffaele, et al.
Publicado: (2020)

Erenumab in the Treatment of Comorbid Trigeminal Neuralgia in Patients With Migraine
por: Katsuki, Masahito, et al.
Publicado: (2023)

Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study
por: Diener, Hans-Christoph, et al.
Publicado: (2021)

Efficacy and safety of erenumab in women with a history of menstrual migraine
por: Pavlovic, Jelena M., et al.
Publicado: (2020)

Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
por: Manickam, Agaath Hedina, et al.
Publicado: (2021)

Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes
por: De Matteis, Eleonora, et al.
Publicado: (2022)

Serum CGRP in migraine patients using erenumab as preventive treatment
por: de Vries Lentsch, Simone, et al.
Publicado: (2022)

Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial
por: Reuter, Uwe, et al.
Publicado: (2021)

A prospective real-world analysis of erenumab in refractory chronic migraine
por: Lambru, Giorgio, et al.
Publicado: (2020)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
por: Raffaelli, Bianca, et al.
Publicado: (2019)

Additive Interaction Between Onabotulinumtoxin-A and Erenumab in Patients With Refractory Migraine
por: Silvestro, Marcello, et al.
Publicado: (2021)

MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
por: Belvís, Robert, et al.
Publicado: (2021)

Improved Osteoarthritis during Erenumab Treatment for Migraine: A Case Report
por: Jantzen, Frederik Thal, et al.
Publicado: (2023)

Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab
por: Giamberardino, Maria Adele, et al.
Publicado: (2017)

Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study
por: Wang, Shuu-Jiun, et al.
Publicado: (2021)

Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double‐blind, placebo‐controlled studies
por: Hirata, Koichi, et al.
Publicado: (2022)

A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study
por: Yu, Shengyuan, et al.
Publicado: (2022)

Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine
por: Popoff, Evan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8v9tbhqf01kfgbkrnagbffiotc